<div id="readability-page-1"><p>Saratoga Research &amp; Investment Management cut its holdings in  Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 2.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,978,134 shares of the company's stock after selling 44,075 shares during the period. Roche accounts for  4.3% of Saratoga Research &amp; Investment Management's portfolio, making the stock its 9th largest holding. Saratoga Research &amp; Investment Management's holdings in Roche were worth $80,629,000 as of its most recent SEC filing.</p><ul><li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li></ul><p>A number of other hedge funds have also recently modified their holdings of the business. Rhumbline Advisers raised its holdings in  Roche by 7.4% in the 1st quarter. Rhumbline Advisers now owns 107,252 shares of the company's stock worth $4,413,000 after purchasing an additional 7,374 shares during the period.  OLD National Bancorp IN raised its stake in shares of  Roche by 2.9% in the second quarter. OLD National Bancorp IN now owns 261,317 shares of the company's stock worth $10,604,000 after buying an additional 7,326 shares during the period.  Enterprise Financial Services Corp bought a new position in shares of  Roche in the second quarter worth about $208,000.  FineMark National Bank &amp; Trust purchased a new position in shares of  Roche during the 2nd quarter valued at about $210,000.  Finally, North Star Asset Management Inc. grew its stake in shares of  Roche by 52.0% during the 2nd quarter. North Star Asset Management Inc. now owns 26,305 shares of the company's stock valued at $1,072,000 after acquiring an additional 9,000 shares during the period. </p><h2>Analysts Set New Price Targets</h2><p>A number of research firms have commented on RHHBY. JPMorgan Chase &amp; Co. upgraded shares of Roche from an &#34;underweight&#34; rating to a &#34;neutral&#34; rating in a research note on Monday, December 8th. Morgan Stanley  reaffirmed an &#34;underweight&#34; rating on shares of Roche in a report on Tuesday, December 2nd. Zacks Research lowered Roche from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Friday, December 5th. HSBC  restated a &#34;buy&#34; rating and issued a $57.00 price objective on shares of Roche in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft raised Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, November 11th. Three analysts have rated the stock with a Strong Buy rating, one  has given a Buy rating, two have issued  a Hold rating and two have issued  a Sell rating to the stock. According to MarketBeat, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $57.00.</p><ul><li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li></ul><p><b>Get Our Latest Stock Report on RHHBY</b></p><h2>Roche Stock Performance</h2><p>Shares of Roche stock opened at $50.04 on Friday. Roche Holding AG has a twelve month low of $34.10 and a twelve month high of $50.67. The business has a 50-day moving average price of $45.44 and a 200-day moving average price of $42.31. </p><h2>Roche Profile</h2> (Free Report)<ul><li>NVIDIA Invested in These 2 AI Stocks, Should You? </li></ul><p>Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Roche</li><li>What is a support level?</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li><li>Large Cap Stock Definition and How to Invest</li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>Why Are Stock Sectors Important to Successful Investing?</li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Roche Right Now?</h2><p>Before you consider Roche, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.</p><p>While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RHHBY

<p>Saratoga Research & Investment Management reduced its holdings in Roche Holding AG by 2.2% in Q2, now owning 1,978,134 shares worth $80.63 million. Roche is the firm's 9th largest holding, accounting for 4.3% of its portfolio. Other hedge funds also adjusted their positions in Roche. Analysts have mixed ratings on Roche, with an average rating of 'Moderate Buy' and a price target of $57.00.</p>

Saratoga Research & Investment Management Has $80.63 Million Position in Roche Holding AG $RHHBY